Literature DB >> 26744458

High-dose dexamethasone corrects impaired myeloid-derived suppressor cell function via Ets1 in immune thrombocytopenia.

Yu Hou1, Qi Feng1, Miao Xu2, Guo-Sheng Li3, Xue-Na Liu2, Zi Sheng2, Hai Zhou2, Ji Ma4, Yu Wei2, Yuan-Xin Sun2, Ying-Yi Yu2, Ji-Hua Qiu2, Lin-Lin Shao2, Xin-Guang Liu2, Ming Hou5, Jun Peng1.   

Abstract

Myeloid-derived suppressor cells (MDSCs) are heterogeneous immature cells and natural inhibitors of adaptive immunity. In this study, the MDSC population was evaluated in adult patients with primary immune thrombocytopenia (ITP), where cell-mediated immune mechanisms are involved in platelet destruction. Our data demonstrated that both the numbers and suppressive functions of MDSCs were impaired in the peripheral blood and spleens of patients with ITP compared with healthy control patients. High-dose dexamethasone (HD-DXM) treatment rescued MDSC numbers in patients with ITP. And DXM modulation promoted the suppressive function of MDSCs induced in vitro. Moreover, the expression of interleukin 10 and transforming growth factor β was significantly upregulated in DXM-modulated MDSCs compared with the unmodulated cultures. DXM-modulated MDSCs inhibited autologous CD4(+)T-cell proliferation and significantly attenuated cytotoxic T lymphocyte-mediated platelet lysis, further indicating enhanced control over T-cell responses. Elevated expression of the transcription factor Ets1 was identified in DXM-modulated MDSCs. Transfection of Ets-1 small interfering RNA efficiently blocked regulatory effects of MDSCs, which almost offset the augmentation of MDSC function by DXM. Meanwhile, splenocytes from CD61 knockout mice immunized with CD61(+)platelets were transferred into severe combined immunodeficient (SCID) mouse recipients (C57/B6 background) to induce a murine model of severe ITP. We passively transferred the DXM-modulated MDSCs induced from bone marrow of wild-type C57/B6 mice into the SCID mouse recipients, which significantly increased platelet counts in vivo compared with those receiving splenocyte engraftment alone. These findings suggested that impaired MDSCs are involved in the pathogenesis of ITP, and that HD-DXM corrected MDSC functions via a mechanism underlying glucocorticoid action and Ets1.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26744458     DOI: 10.1182/blood-2015-10-674531

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity.

Authors:  Sara Falck-Jones; Sindhu Vangeti; Meng Yu; Ryan Falck-Jones; Alberto Cagigi; Isabella Badolati; Björn Österberg; Maximilian Julius Lautenbach; Eric Åhlberg; Ang Lin; Rico Lepzien; Inga Szurgot; Klara Lenart; Fredrika Hellgren; Holden Maecker; Jörgen Sälde; Jan Albert; Niclas Johansson; Max Bell; Karin Loré; Anna Färnert; Anna Smed-Sörensen
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

2.  Impaired glucocorticoid receptor expression and mitochondrial metabolism in MDSCs contribute to glucocorticoid resistance in immune thrombocytopenia.

Authors:  Rick Kapur
Journal:  Cell Mol Immunol       Date:  2022-06-15       Impact factor: 22.096

3.  Glucocorticoid receptor modulates myeloid-derived suppressor cell function via mitochondrial metabolism in immune thrombocytopenia.

Authors:  Yu Hou; Jie Xie; Shuwen Wang; Daqi Li; Lingjun Wang; Haoyi Wang; Xiaofei Ni; Shaoqiu Leng; Guosheng Li; Ming Hou; Jun Peng
Journal:  Cell Mol Immunol       Date:  2022-04-12       Impact factor: 22.096

4.  SIRT1 single-nucleotide polymorphisms are associated with corticosteroid sensitivity in primary immune thrombocytopenia patients.

Authors:  Shuwen Wang; Xiaoyu Zhang; Shaoqiu Leng; Yanqi Zhang; Ju Li; Jun Peng; Zeping Zhou; Qi Feng; Xiang Hu
Journal:  Ann Hematol       Date:  2021-07-16       Impact factor: 3.673

5.  Distinct alterations of CD68+CD163+ M2-like macrophages and myeloid-derived suppressor cells in newly diagnosed primary immune thrombocytopenia with or without CR after high-dose dexamethasone treatment.

Authors:  Xia Shao; Boting Wu; Luya Cheng; Feng Li; Yanxia Zhan; Chanjuan Liu; Lili Ji; Zhihui Min; Yang Ke; Lihua Sun; Hao Chen; Yunfeng Cheng
Journal:  J Transl Med       Date:  2018-03-02       Impact factor: 5.531

6.  High-Dose Dexamethasone Alters the Increase in Interleukin-16 Level in Adult Immune Thrombocytopenia.

Authors:  Xinru Wang; Lizhen Li; Yuanjian Wang; Xin Li; Qi Feng; Yu Hou; Chunhong Ma; Chengjiang Gao; Ming Hou; Jun Peng
Journal:  Front Immunol       Date:  2019-03-18       Impact factor: 7.561

Review 7.  Context-Dependent Effect of Glucocorticoids on the Proliferation, Differentiation, and Apoptosis of Regulatory T Cells: A Review of the Empirical Evidence and Clinical Applications.

Authors:  Luigi Cari; Francesca De Rosa; Giuseppe Nocentini; Carlo Riccardi
Journal:  Int J Mol Sci       Date:  2019-03-06       Impact factor: 5.923

8.  Clinical Significance of Tumor Infiltrating Lymphocytes in Association with Hormone Receptor Expression Patterns in Epithelial Ovarian Cancer.

Authors:  Gwan Hee Han; Ilseon Hwang; Hanbyoul Cho; Kris Ylaya; Jung-A Choi; Hyunja Kwon; Joon-Yong Chung; Stephen M Hewitt; Jae-Hoon Kim
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

9.  Indirubin modulates CD4+ T-cell homeostasis via PD1/PTEN/AKT signalling pathway in immune thrombocytopenia.

Authors:  Yajing Zhao; Panpan Han; Lei Liu; Xiaojie Wang; Pengcheng Xu; Haoyi Wang; Tianshu Yu; Yunqi Sun; Lizhen Li; Tao Sun; Xinguang Liu; Hai Zhou; Jihua Qiu; Liang Wang; Jun Peng; Shuqian Xu; Ming Hou
Journal:  J Cell Mol Med       Date:  2019-01-04       Impact factor: 5.310

Review 10.  Immunotherapies for malignant glioma.

Authors:  Vassiliki A Boussiotis; Alain Charest
Journal:  Oncogene       Date:  2017-12-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.